Biosimilars are biological medicinal products that are similar to another biological product that has already been authorized and which do not differ significantly from the original product in terms of quality safety and efficacy.
Our biosimilars undergo rigorous clinical studies to demonstrate interchangeability with the reference product. “Similar” refers to the fact that the product is highly similar to the reference product and that there are no clinically meaningful differences between the two products in functionality or safety.
Biosimilars are copies of biological medicines that are already approved. Biosimilars therefore make these medicines more accessible to those who might not otherwise be able to afford them and, at the same time, offer patients the best treatments available.
As large innovator biologics lose patent protection, payers become more incentivized to support biosimilar market adoption; Lower cost alternatives facilitate cost containment and healthcare sustainability.